ESC/EAS Guidelines for the management of dyslipidaemias
Рекомендации ESC/EAS по лечению дислипидемий: Рабочая группа Европейского общества кардиологов (ESC) и Европейского общества атеросклероза (EAS) по лечению дислипидемий
2011-01-01
SCID: 54.1/mdtaes95
Discuss with AI
ESC/EAS guidelinesatherosclerosiscardiovascular disease preventioncoronary artery diseasedyslipidaemia management
Figures from the paper
Abstract (AI)
Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies’ Task forces on CVD prevention in clinical practice.2 – 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.
Key Findings
1
Atherosclerotic cardiovascular disease and thrombosis are Europe’s leading causes of premature mortality and disability-adjusted life years, with substantial economic costs.
2
Dyslipidaemia prevention and treatment should be integrated with broader Joint European Societies’ cardiovascular prevention guidelines rather than considered in isolation.
3
Dyslipidaemias, alongside smoking, inactivity, diet, hypertension, and type 2 diabetes, are important modifiable cardiovascular risk factors.
4
The guidelines establish dyslipidaemia management as an essential, integral component of comprehensive cardiovascular disease prevention.
5
The recommendations address both general clinicians involved in prevention and lipid specialists managing difficult-to-classify or difficult-to-treat dyslipidaemias.
Research Object
Dyslipidaemias (disorders of blood lipids) as managed in clinical practice
Research Subject
The prevention and treatment management of dyslipidaemias, including their classification and management in difficult-to-treat cases
Publication Details
Publication Date
2011-01-01
Journal
Publisher
ISSN
Cited by
3537
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai7
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)2012
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation2008
Statins for the primary prevention of cardiovascular disease2013
Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction2002
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials2009
Fish Oil and the Management of Hypertriglyceridemia2009
Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease2001
Cited by19
2013 ESH/ESC Guidelines for the management of arterial hypertension2013
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2016
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk2019
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)2012
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 20122012
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2016
2013 ESH/ESC Guidelines for the management of arterial hypertension2013
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2019
European guidelines on cardiovascular disease prevention in clinical practice: executive summary2007
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2013
Statins for the primary prevention of cardiovascular disease2013
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)2016
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 22015
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension2013
The Agenda for Familial Hypercholesterolemia2015
Statin Therapy: Review of Safety and Potential Side Effects.2016
Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence2019
Effects of Coenzyme Q10 on Statin‐Induced Myopathy: An Updated Meta‐Analysis of Randomized Controlled Trials2018